Replication data for: The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors

Principal Investigator(s): View help for Principal Investigator(s) Craig L. Garthwaite

Name	File Type	Size	Last Modified
AEJ_APPl-2010-0292_Files			10/12/2019 03:59:PM
LICENSE.txt	text/plain	14.6 KB	10/12/2019 11:59:AM

Project Citation:

Garthwaite, Craig L. Replication data for: The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors. Nashville, TN: American Economic Association [publisher], 2012. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2019-10-12. https://doi.org/10.3886/E113822V1

Project Description

Summary: Despite dramatic improvements in medical technology, little attention has been paid to the role of these innovations in improving economic outcomes. This study estimates the labor supply effects of Cox-2 inhibitors, a widely prescribed class of pharmaceuticals used for the treatment of chronic pain and inflammation and primarily marketed under the brand names Vioxx, Celebrex, and Bextra. This paper exploits the removal of Vioxx from the market in 2004 as an exogenous change in drug use. This removal was associated with a 0.35 percentage point decrease in overall labor force participation and $19 billion in lost wages. (JEL I12, J22, L65, O31).

Scope of Project

JEL Classification:
      I12 Health Behavior
      J22 Time Allocation and Labor Supply
      L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics
      O31 Innovation and Invention: Processes and Incentives

Related Publications

Download this project

Published Versions

V1 [2019-10-12]

Export Metadata

Dublin Core

DDI 2.5

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.